AOA Dx, a NYC-based company developing a detection test for ovarian cancer, raised $17M in funding.
The round was led by Good Growth Capital with participation from RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures with diagnostic investors, including Labcorp Venture Fund.
The company intends to use the funds to open new lab facilities, expand their ovarian cancer prospective clinical trial (OVERT) and develop the GlycoLocate™ platform into various new cancer areas.
Led by Oriana Papin-Zoghbi, CEO and Co-Founder, AOA Dx is working in the field of glycolipids through the utilization of tumor marker gangliosides. With an initial focus on ovarian cancer, their platform technology, GlycoLocate™, will harness novel biomarkers through data science, offering improvements in early detection of cancer.
To date, AOA Dx has raised a total of $24M.
FinSMEs
12/10/2023